Notice of Results for Year Ended 31 March 2020

RNS Number : 3774G

Eco Animal Health Group PLC

24 November 2020

 

24 November 2020

ECO Animal Health Group plc

("ECO" or the "Group")

(AIM: EAH)

NOTICE OF RESULTS FOR YEAR ENDED 31 MARCH 2020

CONFIRMATION OF CONTINUED STRONG TRADING

On 11^th September 2020, ECO Animal Health Group plc (the "Group") announced that the Group intended to publish its annual audited accounts for the year ended 31 March 2020 prior to 30 November 2020.  

AIM has granted the Group an additional one month extension to the publication timetable in order to manage additional work arising from auditing the Group's international operations during the Covid-19 pandemic restrictions and against the backdrop of new auditors and new accounting policies adopted at the time of the most recent interim report.  Accordingly, the Group will publish its annual audited accounts during December and prior to 31 December 2020.  The Group's AGM will be held as soon as practicable thereafter. 

The Group provided a trading update on 21 October 2020, noting that the revenue in the six months ended 30 September 2020 would be significantly ahead of management's expectations and the same period for the prior year.  The Group confirms that strong trading has continued during November and, being mindful of the continuing global uncertainties and four months remaining until the end of the financial year, it is confident of meeting market expectations.

Contacts:  

ECO Animal Health Group plc Marc Loomes (CEO) Christopher Wilks (CFO)	020 8447 8899
IFC Advisory Graham Herring Zach Cohen	020 3934 6630
N+1 Singer (Nominated Adviser & Joint Broker) Mark Taylor Peter Steel Alex Bond	020 7496 3000
Peel Hunt LLP (Joint Broker) James Steel Dr Christopher Golden	020 7418 8900

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR").  Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

END

 

 

NORBLBDBDXDDGGS